Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• The transferrin receptor (TfR) plays a crucial role in cell proliferation by mediating iron uptake.
• Its expression is often elevated in rapidly dividing cells, including malignant lymphocytes.
• Understanding TfR expression patterns in non-Hodgkin's lymphomas (NHLs) can provide insights into disease biology and potential therapeutic targets.

Purpose of the Study:

• To investigate the expression of the transferrin receptor using the monoclonal antibody OKT9 in a large cohort of non-Hodgkin's lymphomas.
• To correlate TfR expression with lymphoma lineage (B- and T-cell), morphologic grade, and specific histologic subtypes.
• To examine the relationship between TfR expression and clinical outcomes in selected lymphoma groups.

Main Methods:

• Cryostat sections from 267 cases of non-Hodgkin's lymphomas and related neoplasms were analyzed.
• Immunohistochemical staining was performed using the monoclonal antibody OKT9, which targets the transferrin receptor.
• Staining results were correlated with International Working Formulation morphologic grades and clinical follow-up data.

Main Results:

• The transferrin receptor was expressed in a wide range of B- and T-lineage non-Hodgkin's lymphomas.
• TfR expression generally correlated with higher morphologic grades, with more frequent and intense staining observed in higher-grade lymphomas.
• Specific subtypes showed varied TfR expression patterns not strictly aligned with grade, such as higher expression in follicular low-grade lymphomas compared to diffuse low-grade lymphomas.

Conclusions:

• The transferrin receptor is a common marker across various non-Hodgkin's lymphomas, irrespective of B- or T-cell lineage.
• While generally associated with higher-grade lymphomas, TfR expression exhibits heterogeneity among different histologic subtypes.
• Transferrin receptor expression did not show a significant correlation with survival in chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large cell/immunoblastic lymphoma.